Navigation Links
Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Date:10/21/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the ongoing double blind placebo controlled Phase 1b/2a study in subjects with normal and low HDL is progressing as planned. The subjects in the first group receiving a low dose of RVX-208 show safety and tolerability. Thus the safety committee the has made a decision to commence the next cohort in which 24 subjects will receive treatment doses escalating each week, for a total of 4 weeks.

Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are very pleased to be able to share this exciting clinical information with the Clinical Advisory Board at the American Heart Association meeting on November 8th."

Resverlogix will give an oral presentation during the American Heart Association Scientific Sessions meeting in November 2008 where the Company will present novel data for RVX-208 to attendees. Due to the nature of double blinded clinical trials and strict embargo rules set by the American Heart Association, data from this Phase 1b/2a clinical trial will not be presented in full until the completion of the trial.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT).

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol efflux, in which accumulated chole
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Resverlogix Announces Closing of Debt Redemption
2. Resverlogix Eliminates Sixty Percent of Remaining Debt
3. Resverlogix Issues a Management Statement
4. Resverlogix Board of Directors Update
5. Resverlogix Notice of Conference Call & Webcast
6. Jan Gray Joins Resverlogix Board of Directors
7. Resverlogixs Lead Drug Featured in Key Scientific Publication
8. Industry Leaders Select Resverlogixs RVX-208
9. /C O R R E C T I O N from Source -- Resverlogix Corp./
10. Resverlogix Notice of Conference Call & Webcast
11. Resverlogix Share Option Extension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... its corporate partner, Boston Scientific Corporation (NYSE: ... U.S. Food and Drug Administration (FDA) to market ... a highly deliverable, next-generation drug-eluting stent (DES) specifically ...
... Data from Phase II Study Evaluating Bavituximab in ... Data from Phase I Study Evaluating Bavituximab in ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a ... the treatment of cancer and serious virus infections, ...
... Corporation (NYSE: BSX ) today announced it ... Administration (FDA) to market its TAXUS(R) Liberte (R) ... drug-eluting stent (DES) specifically designed for treating small coronary ... as small as 2.25 mm in diameter and joins ...
Cached Biology Technology:Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 3Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 4Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 5Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 2Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 3Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 4FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4
(Date:4/16/2014)... densely packed array of finger-like projections called microvilli ... line our intestines., Vanderbilt University researchers have now ... which is critical for absorbing nutrients and defending ... the journal Cell , reveal a role ... increase our understanding of intestinal pathologies associated with ...
(Date:4/16/2014)... Geologic and soil processes are to blame for significant ... to a study published recently in the Journal ... soil samples from all corners of Ohio showed that ... level of concern recommended by the U.S. Environmental Protection ... the authors, who note that regulatory levels typically are ...
(Date:4/15/2014)... CA Photosynthesis provides fixed carbon and energy for nearly ... fascinating process remain mysterious. For example, little is known ... in light intensity. More fundamentally, we do not know ... machines that perform photosynthesis in any organism. , , ... reinhardtii is a leading subject for photosynthesis research. ...
Breaking Biology News(10 mins):Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4
... of the worlds leading marine biologists will gather in Auckland ... life from the poles to the tropics. This major meeting ... Marine Life, is being jointly hosted by the National Institute ... Auckland. The Census of Marine Life is ...
... As housing developments sprout across the United States, smart ... concentrated pockets, instead of the more standard and familiar ... on the environment, affecting a smaller portion of the ... for cluster development was to protect open space, farmland, ...
... often focuses only on the numbers of vertebrate animals ... the tropics. But what about the other organisms, ... the species richness of flowering plants and mammals is ... taxonomists, ecologists, and philosophers explored the worlds southernmost forest ...
Cached Biology News:Location, location, location 2Location, location, location 3The conservation lens 2The conservation lens 3
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
...
Guanine nucleotide-binding protein G(k), alpha subunit...
Biology Products: